comparemela.com

Latest Breaking News On - Guimaraes sousa - Page 1 : comparemela.com

Long term study confirms efficacy of ISA Pharmaceuticals T-cell activating immunotherapy in combination with checkpoint inhibitor

/PRNewswire/ ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, today announces.

Zuid hollandUnited statesBonnie glissonet alMichael curranGuimaraes sousaCornelis meliefMd anderson cancer centerBonnie glissonetCancer centerHuman papilloma virusOropharyngeal cancerObjective response rateOverall survivalComplete responseChief scientific officerSynthetic long peptide

Long term study confirms efficacy of ISA Pharmaceuticals T-cell activating immunotherapy in combination with checkpoint inhibitor

- Data published in the Journal of ImmunoTherapy of Cancer confirms efficacy of combination treatment (anti-PD1 + ISA101b) - Deep and durable responses have a profound positive effect

Zuid hollandUnited statesBonnie glissonet alMichael curranGuimaraes sousaCornelis meliefMd anderson cancer centerBonnie glissonetCancer centerHuman papilloma virusOropharyngeal cancerObjective response rateOverall survivalComplete responseChief scientific officerSynthetic long peptide

Long term study confirms efficacy of ISA Pharmaceuticals T-cell activating immunotherapy in combination with checkpoint inhibitor

/PRNewswire/ ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, today announces.

Zuid hollandUnited statesBonnie glissonet alMichael curranGuimaraes sousaCornelis meliefMd anderson cancer centerBonnie glissonetCancer centerHuman papilloma virusOropharyngeal cancerObjective response rateOverall survivalComplete responseChief scientific officerSynthetic long peptide

vimarsana © 2020. All Rights Reserved.